TrialPath
Recruiting

Systemic Lupus Erythematosus and Accelerated Aging

NCT05698173 · University Hospital, Bordeaux
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

About this study
Systemic lupus erythematosus (SLE) is a chronic systemic autoimmune disease characterized by a breakdown of tolerance against nuclear antigens. Thanks to improvements during the last decades in diagnosis, therapeutics and medical care, the lifespan of SLE patients has remarkably increased. However, standardized mortality ratio are still high in this population, with an increased mortality and morbidity associated with cardiovascular events and infectious events. Interestingly, these conditions are more commonly found during old age in the general population, raising the question of the presence of an acceleration of the aging process in SLE patients. It has been demonstrated that the aging of the immune system, i.e. immunosenescence, is a key player in the development of many age-related diseases. The acceleration of immunosenescence, as it is observed during chronic viral infections for example, could favor the premature occurrence of clinical manifestations of accelerated aging. The exact contribution of such phenomenon in the context of SLE has, so far, never been explored. Here, the investigators propose to perform a comprehensive study of the phenomena of immune system aging in patients with SLE in comparison to age-matched healthy controls. The study will recruit 50 SLE patients followed in Bordeaux University Hospital. Among classical disease activity information, blood samples will be collected at study visit to extensively evaluate immune system aging. Fundamental research will be realized on patients' samples. Patients will be included within their usual follow-up. No extra visit will be needed, and blood samples will be drawn at the same time as those drawn for clinical purposes.
Eligibility criteria
Inclusion Criteria: * male or female; * age between 18 and 60 years; * Lupus patient : diagnosis of systemic lupus erythematosus according to ACR or SLICC criteria; * being affiliated to health insurance; * willing to participate and to sign informed consent. Exclusion Criteria: * pregnant or breastfeeding women; * persons deprived of their liberty by a judicial or administrative decision, minors, persons of legal age who are the object of a legal protection measure or unable to express their consent
Study design
Enrollment target: 75 participants
Allocation: non_randomized
Masking: none
Age groups: adult
Timeline
Starts: 2023-09-08
Estimated completion: 2026-09
Last updated: 2025-09-04
Interventions
Biological: blood sampleBiological: blood sample
Primary outcomes
  • Absolute numbers of naïve T lymphocytes (At baseline (Day 0))
Sponsor
University Hospital, Bordeaux · other
With: University of Bordeaux, Institut National de la Santé Et de la Recherche Médicale, France
Contacts & investigators
ContactNoemie GENSOUS, MD · contact · noemie.gensous@chu-bordeaux.fr · (0)5 56 79 58 28
InvestigatorNoemie GENSOUS, MD · principal_investigator, University Hospital, Bordeaux
All locations (1)
CHU de Bordeaux - Médecine Interne et Immunologie CliniqueRecruiting
Bordeaux, France
Systemic Lupus Erythematosus and Accelerated Aging · TrialPath